Viewing Study NCT01224093


Ignite Creation Date: 2025-12-25 @ 12:59 AM
Ignite Modification Date: 2025-12-25 @ 11:12 PM
Study NCT ID: NCT01224093
Status: COMPLETED
Last Update Posted: 2016-11-02
First Post: 2010-10-18
Is NOT Gene Therapy: False
Has Adverse Events: False

Brief Title: An Observational Study on the Safety Profile of MabThera/Rituxan (Rituximab) in Combination With Chemotherapy in Patients With B Cell-lineage Chronic Lymphocytic Leukaemia (MABERYC)
Sponsor: Hoffmann-La Roche
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module